Bugworks Research Incis A Clinical Stage Biopharmaceutical Company Focused On Developing Innovative Therapies To Address Antimicrobial Resistanceamrand Cancerheadquartered In The Usawith Subsidiaries In India And Australiabugworks Is Committed To Making Healthcare Solutions Accessible Globally The Company Is Pioneering A New Class Of Broad Spectrum Antibiotics Through Its Proprietary Eludea C Platformwhich Has Led To The Development Of Gyroxa Series Of Antibiotics Effective Against Drug Resistant Bacteriathe Lead Assetgyrox 1Is Designed For Critical Care Infections And Has Completed Pre Clinical Studiesadditionallybugworks Is Advancing A Portfolio Of Novel Anticancer Agents Targeting Hypoxic Tumorswith Its Lead Candidate Ready For Investigational New Drug Submission Bugworks Collaborates With Various Organizationsincluding The Global Antibiotic Research And Development Partnershipto Enhance Its Research Effortsthe Company Has Received Notable Recognitionincluding The Carb X Granthighlighting Its Innovative Approach To Tackling Amrwith A Dedicated Teambugworks Is Making Significant Contributions To Biotechnology Research
